Biotech | 06 April 2022
BioFluidica to introduce next-generation biomarker isolation platform
BioFluidica LiquidScan harnesses the power of microfluidics
BioFluidica LiquidScan harnesses the power of microfluidics
The aim is to pursue methylation-based tools to better understand biological reactions to pharmaceuticals
Iktos and Teijin Pharma will collaborate in developing new AI technology aiming to bring further improvement and speed to the drug design process
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
The partnership demonstrates increasing adoption of tetra data to create unrestricted innovation
Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target
Trescal provides precision calibration expertise in every industry, geography and instrument across the world
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Supply increase to help meet growing global demand
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Through this partnership, Premas will connect with genomics labs to provide automated NGS solutions
No new studies have been requested
BVX-0922 to target colorectal cancer under investigator-sponsored IND
Subscribe To Our Newsletter & Stay Updated
